Skinner D G
Br J Urol. 1977 Nov;49(6):553-60. doi: 10.1111/j.1464-410x.1977.tb04205.x.
Experience in the management of 146 consecutive patients with non-seminomatous tumours of the testis has led to a plan of management based on retroperitoneal lymph node dissection as the primary treatment modality, with use of adjuvant therapy dependent on pathological findings. Chemotherapy has proved to be the most important adjuvant with postoperative radiation therapy reserved only for patients with extensive retroperitoneal metastatic disease. 3-year crude survival for patients with all stages of disease was 78% and in those in whom the disease was confined to below the diaphragm the survival rate was 85%.
对146例连续性睾丸非精原细胞瘤患者的管理经验，促成了一项以腹膜后淋巴结清扫作为主要治疗方式的管理计划，辅助治疗则根据病理结果使用。化疗已被证明是最重要的辅助治疗手段，术后放疗仅适用于腹膜后转移广泛的患者。所有疾病分期患者的3年粗生存率为78%，而疾病局限于膈肌以下的患者生存率为85%。
